Class III receptor tyrosine kinases: Role in leukaemogenesis

British Journal of Haematology

Volumn 116, Issue 4, 2002, Pages 744-757

  Reilly, John T ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

c fms; c kit; FLT3; Pathogenesis; PDGFR ; RTK class III

Indexed keywords

ASPARTIC ACID; COLONY STIMULATING FACTOR 1; CYTOKINE; GLYCOPROTEIN; GROWTH FACTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; MEMBRANE PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; PROTEIN P85; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; SERINE; THREONINE;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SEQUENCE; BINDING SITE; CELL ACTIVITY; CELL LINEAGE; DIMERIZATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE LOCATION; GENE MUTATION; GENE STRUCTURE; HEMATOPOIESIS; HUMAN; LEUKEMOGENESIS; LIGAND BINDING; LYMPHOMA; MAST CELL LEUKEMIA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR AFFINITY; REVIEW; SIGNAL TRANSDUCTION; TANDEM REPEAT;

ANIMALS; ARTIFICIAL GENE FUSION; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION; HUMANS; LEUKEMIA, MYELOID; MASTOCYTOSIS; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFORMATION, GENETIC;

EID: 0036124762     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0007-1048.2001.03294.x     Document Type: Review

References (164)

1. Fusion of the platelet-derived growth factor b to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution
2. FLT3 internal tandem duplication mutations in adult myeloid leukaemia define a high risk group
3. Genomic structure of human FLT3: Implications for mutational analysis
4. Identification of novel FLT3 Asp835 mutations in adult acute myeloid leukaemia
5. Genomic structure of the downstream part of the human FLT3 gene: Exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III
6. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells. B cells, and myelomonocytic cells in patients with mastocytosis
7. Effects of the tyrosine-kinase inhibitor STI571 on mutated kit and neoplastic mast cells
8. Genomic organization of the c-kit gene: Evolution of the receptor tyrosine kinase subclass III
9. Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow
10. Translocation t(5;12) (q31-q33;p12-p13): A non-random translocation associated with a myeloid disorder with eosinophilia
11. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent c-kit mutation
12. c-kit mutations in core binding factor leukemias
13. Atypical chronic myelomono-cytic leukemia with eosinophilia and translocation (5;12). A new association?
14. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family
15. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages
16. Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor
17. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
18. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: A possible explanation for divergent clinical behavior
19. The TEL/platelet-derived growth factor b receptor (PDGFbR) fusion in chronic myelomonocytic leukemia is a transforming protein that self associates and activates PDGFbR kinase-dependent signalling pathways
20. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL. TEL-ABL, and TEL-PDGFb fusion proteins
21. The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia
22. Internal tandem duplication of the FLT3 gene in acute leukemia: Clinical and prognostic implications in acute myeloid leukemia
23. Signal transduction by the PDGF receptors
24. cDNA cloning and expression of the human A-type platelet-derived growth factor (PDGF) receptor establishes structural similarity to the B-type PDGF receptor
25. Structural alteration of viral homologue of receptor proto-oncogene fms at C terminus
26. Random mutagenesis of CSF-1 receptor (FMS) reveals multiple sites for activating mutations within the extracellular domain
27. McDonough feline sascoma virus: Characterization of the molecularly cloned provirus and its feline oncogene (v-fms)
28. Expression of FLT3 receptor and response of to FLT3 ligand by leukemic cells
29. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells
30. Mutation analysis of c-kit in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis
31. Incidence and prognostic significance of internal tandem duplications of the FLT3 gene in AML, with normal cytogenetics: Analysis of 84 patients treated within the multicenter trial AML HD93
32. Expression of the c-kit gene product in normal and neoplastic mast cells but not in neoplastic basophil/mast cell precursors from chronic myeloid leukemia
33. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product
34. c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia
35. Inhibition of human natural killer cell activity by platelet-derived growth factor (PDGF) III. Membrane binding studies and differential biological effects of recombinant PDGF isoforms
36. Organization and nucleotide sequence of the human KIT (Mast/stem cell growth factor receptor) proto-oncogene
37. Frequent c-fms activation by proviral insertion in mouse myeloblastic leukaemias
38. Selection of activating mutations of c-fms in FDC-P1 cells
39. Fusion of PDGF receptor β to a novel ets-like gene. Tel, in chronic myelomonocytic leukemia with t (5; 12) chromosomal translocation
40. Co-expression of the genes for platelet-derived growth factor and its receptor in human T-cell lines infected with HTLV-1
41. Cloning and characterisation of H4 (D10S170), a gene involved in RET rearrangements in vivo
42. Point mutations in the FLT3 gene in AML
43. Chromosomal localization of the human c-fms oncogene
44. The human PDGF receptor alpha-sub-unit gene maps to chromosome 4 in close proximity to c-kit
45. Leukemic predisposition of mice transplanted with gene-modified hematopoietic precursors expressing flt3 ligand
46. Tandem-duplicated flt3 constitutively activates STAT5 and MAP kinase and induces autonomous cell growth in Il-3-dependent cell lines
47. STI571 inhibits the kinase activity of wild type and juxtamem-brane c-kit mutants but not the exon 17 D816V mutation associated with mastocytosis
48. Mechanism of action and in vivo role of platelet-derived growth factor
49. Gain-of-function mutations of human gastrointestinal stromal tumors
50. Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan
51. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia
52. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells
53. Characterization of a yeast artificial chromosome from human chromosome band 13q12 containing the FLT1 and FLT3 receptor-type tyrosine kinase genes
54. Expression of platelet-derived growth factor b receptor on human monocyte-derived macrophages and effects of platelet-derived growth factor BB dimer on the cellular function
55. A single amino acid substitution in a WW-like domain of diverse members of the PDGF receptor subfamily of tyrosine kinases causes constitutive receptor activation
56. High expression but no internal tandem duplication of FLT3 in normal haematopoietic cells
57. Internal tandem duplication of the FLT3 gene and clincal evaluation in childhood acute myeloid leukemia
58. Active and inactive protein kinases: Structural basis for regulation
59. A domain of TEL conserved in a subset of ETS proteins defines a specific oligo-merization interface essential to the mitogenic properties of the TEL-PDGFR oncoprotein
60. HIP1, a human homologue of S. cerevisiae SIa2p, interacts with membrane-associated huntingtin in the brain
61. Basis of hematopoietic defects in platelet-derived growth factor (PDGF)-B and PDGF β-receptor null mice
62. Expression, function and activation of the proto-oncogene c-kit product in human leukemia cells
63. Structure, organization, and transcription units of the human b-platelet-derived growth factor receptor gene, PDGFRA
64. Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils: A non-randomassociation
65. Truncation of the human EGF receptor leads to differential transforming potentials in primary avian fibroblasts and erythroblasts
66. c-kit point mutations in patients with myeloproliferative disorders
67. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines
68. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia
69. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia
70. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of product
71. Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukaemia
72. The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the MRC AML 10 and 12 trials
73. Fusion of H4/D10S170 to the platelet-derived growth factor receptor β in bcr-abl negative myeloproliferative disorders with a t (5; 10) (q33;q21)
74. Myelodysplastic syndrome associated with increased bone marrow fibrosis and translocation (5;12) (q33;p12.3)
75. Platelet-derived growth factor-stimulated migration of murine fibroblasts is associated with epidermal growth factor receptor expression and tyrosine phosphorylation
76. Activating and dominant inactivating c-kit catalytic domain mutations in distinct clinical forms of human mastocytosis
77. Classes of c-kit activating mutations: Proposed mechanisms of action and implications for disease classification and therapy
78. c-kit ligand and Flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities
79. Inhibition of spontaneous receptor phos-phorylation by residues in a putative β-helix in the kit intracel-lular juxtamembrane region
80. Indoline derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells
81. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors
82. Rabaptin-5, a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelo-monocytic leukemia
83. Independent expression of human alpha or beta platelet-derived growth factor cDNAs in a naive hematopoietic cell leads to functional coupling with mitogenic and chemotactic signaling pathways
84. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations
85. Expression of FLT3 receptor and FLT-3 ligand in human leukemia-lymphoma cell lines
86. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia
87. Genetic aberrations in the development and subsequent progression of myelodysplastic syndrome
88. Multiple signalling pathways mediate leukemogenic activity of internal tandem duplication mutations of FLT3 in AML
89. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways
90. Cell specific transformation by c-fms activating loop mutations is attributable to constitutive receptor degradation
91. Tyrosine phosphorylation in vivo associated with v-fms transformation
92. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder
93. Molecular evolution of acute myeloid leukemia in relapse: Unstable N-ras and FLT3 genes compared with p53 gene
94. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia
95. Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: A marker for the monitoring of minimal residual disease
96. c-kit point mutation of extracellular domain in patients with myeloproliferative disorders
97. Signal transducer and activator of transcription 3 activation is required for Asp816 mutant c-kit-mediated cytokine-independent survival and proliferation in human leukemia cells
98. Platelet-derived growth factor and its receptor in blood cell differentiation and neoplasia
99. Isolation of c-kit receptor-expressing cells from bone marrow, peripheral blood, and fetal liver: Functional properties and composite antigenic profile
100. Myelodysplastic syndrome with t (5; 12) (q31; p12-p13) and eosinophilia: A pediatric case with review of literature
101. Oncogenic mutation in the kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1
102. A new c-kit mutation in a case of aggressive mast cell disease
103. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis
104. Cellular signalling pathways: New targets in leukemia therapy
105. Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t (8; 21) fusion protein may contribute to leukemogenesis
106. FMS mutations in myelodysplastic, leukemic, and normal subjects
107. The Tel PDGFRb fusion gene produces a chronic myelo-proliferative syndrome in transgenic mice
108. Tandem linkage of human CSF-1 receptor (c-fms) and PDGF receptor genes
109. The protein tyrosine family of the human genome
110. Nasal-type T/NK lympho-mas: A clinicopathologic study of 13 cases
111. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the FLT3 gene
112. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family
113. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells
114. Close physical linkage of the FLT1 and FLT3 genes on chromosome 13 in man and chromosome 5 in mouse
115. Expression and signal transduction of the FLT3 tyrosine kinase receptor
116. Fusion of Huntingtin Interacting Protein 1 to platelet-derived growth factor β receptor (PDGFbR) in chronic myelo-monocytic leukemia with t (5;7) (q33; q11.2)
117. Transforming potential of the c-fms proto-oncogene (CSF-1 receptor)
118. A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential
119. Specific binding of the mononuclear phagocyte colony-stimulating factor CSF-1 to the product of the v-fms oncogene
120. Mechanisms of mutagenesis in mammalian cells. Applications to human thyroid tumours
121. H4 (D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor b gene in atypical chronic myeloid leukemia with t (5; 10) (q33;q22)
122. Direct sequencing of the N-ras, c-fms and p53 loci for transforming mutations in myelomonocytic leukaemia
123. Colony-stimulating factor-1 receptor
124. The c-fms proto-oncogene is related to the receptor for the mono-nuclear phagocyte growth factor
125. New reciprocal translocation t (5; 10) (q33;q22) associated with atypical chronic myeloid leukaemia
126. c-kit is expressed by primitive human hematopoietic cells that give rise to colony-forming cells in stroma-dependent or cytokine-supplemented culture
127. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
128. Detection of c-kit mutation Asp816 to Val in microdissected bone marrow infil-trates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia
129. Systemic mastocytosis associated with acute myeloid leukemia: Report of two cases and detection of the c-kit mutation Asp816 to Val
130. c-fms point mutations in acute myeloid leukaemia: Fact or fiction?
131. KRAS oncogene overexpression in myelodysplastic syndrome with translocation 5: 12
132. Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts
133. Identification of novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFBR) gene in BCR-ABL negative chronic myeloproliferative disorders
134. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukaemia
135. Quantitative determination of FLT3 internal tandem repeat (ITD) mutations defines a subgroup with poor prognosis in standard risk AML
136. Activating c-kit mutations in human germ cell tumors
137. Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia
138. TEL/PDGFβR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor
139. Fatal myeloproliferation, induced in mice by TEL/PDGFbR expression, depends on PDGFbR tyrosines 579/581
140. Functional receptor for GDNF encoded by the c-ret proto-oncogene
141. Expression of platelet-derived growth factor and its receptors by two pre-B acute lymphocytic leukemia cell lines
142. Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor
143. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation
144. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation
145. Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3
146. Constitutive activation of c-kit in FMA3 murine masto-cytoma cells caused by deletion of seven amino acids at the juxtamembrane domain
147. Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self association not at the ligand-induced dimerization site
148. Signal transduction by receptors with tyrosine activity
149. Oncogenic activation of the alpha PDGFR defines a domain that negatively regulates receptor dimerization
150. The expression of the proto-oncogene c-kit in the blast cells of acute myeloblastic leukemia
151. Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus
152. Switching signals on and off by receptor dimerization
153. T (5; 12) (q31;p12): A clinical entity with features of both myeloid leukemia and chronic myelomonocytic leukemia
154. Activation of the feline c-fms proto-oncogene: Multiple alterations are required to generate a fully transformed phenotype
155. Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis
156. Cytogenetic abnormalities and their lack of relationship to the Asp816Val mutation in the pathogenesis of mastocytosis
157. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children
158. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
159. Overexpression of PDGF-B in murine hematopoietic cells induces a lethal myeloprolifer-ative syndrome in vivo
160. Identification of PDGF receptors on human megakaryocytes and megakaryocytic cell lines
161. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors
162. Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand
163. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines
164. In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor